Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Recurrence 1NSCLC 1

Interventions

Blood Specimen Collection 32Surveys and Questionnaires 24Radiotherapy 12Gene Expression Profiling 12Drug Therapy 12Surgical Procedures, Operative 11Bronchoscopy 10Magnetic Resonance Spectroscopy 9Immunotherapy 9Immunohistochemistry 9Tomography, X-Ray Computed 8Specimen Handling 8Observation 8Amplified Fragment Length Polymorphism Analysis 8Polymerase Chain Reaction 7pembrolizumab 6Psychiatric Rehabilitation 6Interviews as Topic 6Carboplatin 6Thoracic Surgery, Video-Assisted 5Reverse Transcriptase Polymerase Chain Reaction 5Microarray Analysis 5Liquid Biopsy 5Chemoradiotherapy 5Bevacizumab 5durvalumab 4Therapeutics 4Paclitaxel 4Nivolumab 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Lung Neoplasms × dacomitinib × Clear all
NCT04721106 2026-02-10

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Pfizer

Completed
188 enrolled
Thoracic

Lung Neoplasms

NCT04609319 2025-05-31

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Pfizer

Completed
307 enrolled 25 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡